291 related articles for article (PubMed ID: 21152937)
1. Clinical and molecular insights into tuberous sclerosis complex renal disease.
Siroky BJ; Yin H; Bissler JJ
Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.
Pirson Y
Nephrol Dial Transplant; 2013 Jul; 28(7):1680-5. PubMed ID: 23413089
[No Abstract] [Full Text] [Related]
7. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
[No Abstract] [Full Text] [Related]
8. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
9. [Recent advance in tuberous sclerosis-related genes and their expression].
Liu J; Piao YS; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):210-2. PubMed ID: 20450774
[No Abstract] [Full Text] [Related]
10. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
Kronick J; Gabril MY; House AA
Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
12. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
13. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.
Janssens P; Van Hoeve K; De Waele L; De Rechter S; Claes KJ; Van de Perre E; Wissing KM; Bammens B; Jansen A; Mekahli D
Pediatr Nephrol; 2018 Nov; 33(11):2085-2093. PubMed ID: 29987458
[TBL] [Abstract][Full Text] [Related]
14. Tuberous sclerosis complex renal disease.
Dixon BP; Hulbert JC; Bissler JJ
Nephron Exp Nephrol; 2011; 118(1):e15-20. PubMed ID: 21071977
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
[TBL] [Abstract][Full Text] [Related]
16. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
17. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
19. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]